Bayer agrees to $7.25 billion proposed settlement over thousands of Roundup cancer lawsuits

Bayer Proposes $7.25 Billion Settlement for Roundup Cancer Lawsuits

JEFFERSON CITY, Mo. — Agrochemical giant Bayer and attorneys representing cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of U.S. lawsuits claiming the company’s popular weedkiller Roundup causes cancer.

The landmark agreement comes at a pivotal moment for the German conglomerate, which has faced mounting litigation since acquiring Monsanto, Roundup’s original manufacturer, in 2018. The settlement aims to address most remaining lawsuits while creating a framework for handling future claims from individuals exposed to the herbicide before Tuesday’s announcement.

“Litigation uncertainty has plagued the company for years, and this settlement gives the company a road to closure,” Bayer CEO Bill Anderson said in announcing the agreement.

Filed in St. Louis Circuit Court in Missouri, home to Bayer’s North American crop science division, the settlement requires court approval before taking effect. Missouri has been a central battleground in the Roundup litigation, with many lawsuits originating in the state.

The settlement would not affect Bayer’s upcoming U.S. Supreme Court case, scheduled for arguments in April, where the company contends that the Environmental Protection Agency’s approval of Roundup without a cancer warning should invalidate claims filed in state courts. However, the agreement helps mitigate risks from that ruling by ensuring patients receive compensation regardless of the Supreme Court’s decision, while protecting Bayer from potentially larger costs if the court rules against it.

Approximately 200,000 Roundup-related claims have been filed against Bayer since 2015, including more than 125,000 lawsuits. Most cases have been settled out of court, with only 24 reaching a verdict—13 in Bayer’s favor and 11 for plaintiffs, including a substantial $2.1 billion award by a Georgia jury last year.

The proposed settlement establishes a compensation fund that Bayer would finance through annual payments over 21 years, totaling up to $7.25 billion. Individual payouts would vary significantly based on factors including exposure type, age at diagnosis, and disease severity.

Agricultural, industrial, or turf workers with long-term Roundup exposure diagnosed with aggressive non-Hodgkin lymphoma before age 60 would receive an average of $165,000. In contrast, residential users diagnosed between ages 60-77 with less aggressive forms would receive approximately $20,000, while those diagnosed at 78 or older would receive around $10,000.

“No settlement can erase a diagnosis, but this agreement is designed to ensure that both today’s and tomorrow’s patients have access to meaningful compensation,” said attorney Christopher Seeger, who would represent current claimants under the settlement.

Not all attorneys view the proposed compensation as adequate. Matt Clement, who represents approximately 280 Roundup plaintiffs, expressed surprise at the settlement terms and anticipated many clients would opt out, calling the proposed payouts “exceedingly too small.”

If too many plaintiffs reject the settlement, Bayer reserves the right to cancel it, though the company has not specified the threshold number of opt-outs that would trigger cancellation.

Bayer has consistently disputed claims that Roundup’s key ingredient, glyphosate, causes cancer, pointing to the EPA’s assessment that the chemical is “not likely to be carcinogenic to humans when used as directed.” The company has already stopped using glyphosate in residential Roundup products sold in the U.S. but continues to include it in agricultural formulations.

The company’s legal strategy extends beyond settlements. Bayer has argued before the Supreme Court that federal pesticide laws preempt state-level failure-to-warn lawsuits when products comply with federal labeling requirements. The Trump administration has supported Bayer’s position in this legal battle, reversing the stance taken by the Biden administration.

Simultaneously, Bayer has pursued legislative shields at the state level. Both North Dakota and Georgia enacted laws in the past year protecting pesticide manufacturers from state failure-to-warn lawsuits when their products follow federal labeling requirements.

The Roundup controversy has significantly impacted Bayer’s finances and reputation since its $63 billion acquisition of Monsanto. The company has warned that continued litigation threatens its ability to sell the product in U.S. agricultural markets, where glyphosate remains a crucial component in farming systems using genetically modified crops engineered to withstand the herbicide.

If approved, the settlement would represent one of the largest mass tort resolutions in recent years and potentially allow Bayer to begin moving beyond a legal challenge that has weighed heavily on its business operations and stock value.